ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.30 +0.13 (+0.64%)

Delayed Quote Updated: 1:24 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Analyst Ratings for ACADIA Pharmaceuticals ↗

March 20, 2023

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug ↗

March 14, 2023

The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older.

Via Benzinga

Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 14, 2023

Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...

Via Benzinga

Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment ↗

March 13, 2023

Via Benzinga

1 Top Biotech Stock to Buy in March ↗

March 07, 2023

This biotech could land a major regulatory approval this month.

Via The Motley Fool

Looking Into ACADIA Pharmaceuticals's Return On Capital Employed ↗

March 02, 2023

Via Benzinga

Analysts See Steady Growth For Acadia Pharma's Nuplazid ↗

February 28, 2023

Via Benzinga

Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket ↗

March 13, 2023

Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...

Via Benzinga

3 Nasdaq Stocks on Watch This Week ↗

March 12, 2023

These three Nasdaq stocks are poised to make big moves in the coming week.

Via The Motley Fool

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

March 10, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

March 03, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

February 28, 2023

Via Benzinga

Earnings Preview For ACADIA Pharmaceuticals ↗

February 24, 2023

Via Benzinga

Analyst Expectations for ACADIA Pharmaceuticals's Future ↗

January 31, 2023

Via Benzinga

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

February 27, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

February 14, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development

January 09, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know ↗

December 21, 2022

Via Benzinga

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics

January 03, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

December 21, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

November 25, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Acadia Trofinetide Phase III Clinical Top-Line Results Positive

November 16, 2022

Via AB Newswire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

November 08, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗

November 04, 2022

Upgrades

Via Benzinga

Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 02, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

October 31, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.